Ambulatory photodynamic therapy

Patent Citations (241)

Non-Patent Literature (114)

• Beems et al., “Photosensitizing properties of bacteriochlorophyllin a and bacteriochlorin a, two derivatives of bacteriochlorophyll a”, Photochem. Photobiol., 46(5):639-643 (1987).Applicant
• Bellnier et al., “Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a”, J. Photochem. Photobiol. B: Biol., 20:55-61 (1993).Applicant
• Blaauwgeers et al., “Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris”, American Journal of Pathology, 155(2):421-428 (1999).Applicant
• Boulton et al., “VEGF localization in diabetic retinopathy”, Br J Ophthalmol, 82:561-568 (1998).Applicant
• Certified English Translation of Japanese Patent Application No. Sho51-159879 (Japanese Kokai [Unexamined Patent] No. 53-84998), “Carcinostatic Method.”Applicant
• Certified English Translation of Japanese Kokai [Unexamined Patent] No. 57-185220, “Anti-Cancer Drug Having Chlorophyll Derivative Effective Component,”.Applicant
• Chen, J., “Next Generation Light Delivery System for Multi-Treatment Extended Duration Photodynamic Therapy (MED-PDT)”, SPIE-Proceedings Series, 2972:161-167 (1997).Applicant
• Chen et al., “New Technology for Deep Light Distribution in Tissue for Phototherapy”, The Cancer J., 8(2):154-163 (2002).Applicant
• De Jode et al., “A comparison of Novel Light Sources for Photodynamic Therapy”, Lasers Med Sci, 12:260-268 (1997).Applicant
• Dougherty, T.J., “A Brief History of Clinical Photodynamic Therapy Development at Roswell Park Cancer Institute”, J. Clin. Laser Med. & Surg., 14(5):219-221 (1996).Applicant
• Dougherty, T.J., “Photosensitization of malignant tumors”, Sem. Sur. Oncol., 2:24-37 (1986).Applicant
• Gagel, M. P., Photodynamic therapy with porphyrins (1997), available at http://www.dermatology.org/laser/pdt.html.Applicant
• Henderson et al., “An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy”, Cancer Res., 57:4000-4007 (1997).Applicant
• Kessel et al., “Photosensitization with bacteriochlorins”, Photochem. Photobiol., 58(2):200-203 (1993).Applicant
• Kozyrev et al., “Effect of substituents in OsO4 reactions of metallochlorins regioselective synthesis of isobacteriochlorins and bacteriochlorins”, Tetrahedron Letters, 37(22):3781-3784 (1996).Applicant
• Mizeret, et al., “Cylindrical Fiberoptic Light Diffuser for Medical Application”, Lasers Surg. Med., 19:159-167 (1996).Applicant
• Pandey et al., “Comparative in vivo sensitizing efficacy of porphyrin and chlorin dimers joined with ester, ether, carbon-carbon or amide bonds”, J. Molecular Recognition, 9:118-122 (1996).Applicant
• Prewett et al., “Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors”, Cancer Research, 59:5209-5218 (1999).Applicant
• Rimington et al., “Preparation and photosensitizing properties of hematoporphyrin ethers”, Free Rad. Res. Comms., 7(3-6):139-142 (1989).Applicant
• Rungta et al., “Purpurinimides as photosensitizers: effect of the presence and position of the substituents in the in vivo photodynamic efficacy”, Bioorg. Medicinal Chem. Letters, 10:1463-1466 (2000).Applicant
• Schmidt-Erfurth et al., “Vascular targeting in photodynamic occlusion of subretinal vessels”, Ophthalmol., 101(12):1953-1961 (1994).Applicant
• Spikes, J.D., “Porphyrins and related compounds as photodynamic sensitizers”, Annals of the New York Academy of Sciences, 244:496-508 (1975).Applicant
• Woodburn et al., “Evaluation of porphyrin characteristics required for photodynamic therapy”, Photochem. Photobiol., 55(5):697-704 (1992).Applicant
• Adili et al., “Local delivery of photosensitizing drugs in arteries: a novel approach to photodynamic therapy for the prevention of intimal hyperplasia”, Proc. SPIE-INT. Soc. Opt. Eng., 2395:402-408 (1995) (Ger. Symp. Laser Angioplasty, 2nd, 1980).Applicant
• Anonymous (1997) http://www.lumacare.com/, 2 pages.Applicant
• Anonymous (May 1998) “The 1998 Photonics Circle of Excellence Award Winners”, Photonics Spectra, pp. 95-96.Applicant
• Article: “Photonics Application of High-Power Semiconductor Diode Laser Technology”, AFRL Technology Horizons, 1(1), 35-36 (2000).Applicant
• Barr et al., “Normal tissue Damage Following Photodynamic Therapy: Are There Biological Advantages?”, Book: Photodynamic Therapy, Basic Principles and Clinical Applications, Barbara W. Henderson and Thomas J. Dougherty, (Eds.); Marcel Dekker, Inc. New York, pp. 201-216.Applicant
• Bärwolff et al., “Semiconductor Diode Lasers: Research and Applications at the Max-Born-Institute”, pp. 1-10 (1995).Applicant
• Bayer et al., “Raw eggs and cancer therapy”, Science Spectra, 12:34-41 (1998).Applicant
• Beems et al., Photosensitizing properties of bacteriochlorophyllin a and bacteriochlorin a, two derivatives of bacteriochlorophyll a, Photochem. Photobiol. 46(5): 639-643 (1987).Applicant
• Bellnier et al., Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a, J. Photochem. Photobiol. B: Biol. 20: 55-61 (1993).Applicant
• Birchler et al., “Selective Targeting and Photocoagulation of Ocular Angiogenesis Mediated by a Phage-Derived Human Antibody Fragment”, Nature Biotechnol., 17:984-988 (1999).Applicant
• Brower, V., “Tumor Angiogenesis—New Drugs on the Block”, Nature Biotechnology., 17:963-968 (1999).Applicant
• Buda, Manuela, “Low-Confinement High-Power Semiconductor Lasers”, Eindhoven University of Technology, The Netherlands (ed.), pp. 58-77 (1999).Applicant
• Casalini et al., “Tumor Pretargeting: Role Of Avidin/Streptavidin On Monoclonal Antibody Internalization”, J.Nuclear Med., 38(9):1878-1381 (1997).Applicant
• Cattel et al., “The Role of Conjugation Processes and Linking Agents in the Preparation of Molecular/Particulate Conjugates—a Review”, S.T.P. Pharma. Sci., 9(4):307-319 (1999).Applicant
• Ciulla et al., “Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy”, Exp. Opin. Invest. Drugs, 8(12):2173-2182 (1999).Applicant
• Dartsch et al., “Photodynamic therapy of vascular stenoses? Response of cultured human smooth muscle cells from non-atherosclerotic arteries and atheromatous plaques following treatment with photosensitizing porphyrins”, Proc. SPIE-INT. Soc. Opt. Eng., 1462:77-80 (1990).Applicant
• Dictionary of Cell Biology, Second Edition (Lackie & Dow, eds., 1989), p. 17.Applicant
• Dillon et al., “In Vitro and In Vivo Protection Against Phototoxic Side Effects of Photodynamic Therapy by Radioprotective Agents WR-2721 and WR-77913”, Photochemistry and Photobiology, 48(2):235-238 (1988).Applicant
• Dimitroff et al., “Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy”, Investigational New Drugs, 17:121-135 (1999).Applicant
• Dougherty et al., Yearly Review “Photodynamic Therapy”, Photochem. Photobiol., 58(6):895-900 (1993).Applicant
• Dougherty et al., Review “Photodynamic Therapy”, J. Nat. Cancer Inst., 90(12):889-905 (1998).Applicant
• Dougherty, T.J., Photosensitization of malignant tumors, Seminars in Surgical Oncology 2:24-37 (1986).Applicant
• Edamatsu et al., “One and Two-Photon Selective Excitation Spectroscopy of CuC1 Quantum Dots”, Review, 17:15-16 (1998).Applicant
• Fact Sheet: Laser Medical Pac, pp. 1-2 (1998).Applicant
• Ferrario et al., “Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma”, Cancer Research, 60:4066-4069 (2000).Applicant
• Fisher et al., “Simultaneous Two-Photon Activation of Type-1 Photodynamic Therapy Agents,” Photochemistry and Photobiology, 66(2), 141-155 (1997).Applicant
• Freiherr, G., “Advances in Photodynamic Therapy Lure Device Innovators”, Medical Device & Diagnostic Industry, http://[email protected], 4 pages.Applicant
• Fukuda, Mitsuo, Reiability and Degradation of Semiconductor Lasers and LEDs, Artech House, Inc., pp. 43-65, 115-118, and 134-136 (1991).Applicant
• Gilson et al., “Therapeutic ratio of photodynamic therapy in the treatment of superficial tumours of skin and subcutaneous tissues in man”, J. Cancer, 58:665-667 (1988).Applicant
• Granville et al., “Photodynamic Treatment with Benzoporphyrin Derivative Monoacid Ring A Produces Protein Tyrosine Phosphorylation Events and DNA Fragmentation in Murine P815 Cells”, Photochem. Photobiol., 67(3):358-362 (1998).Applicant
• Haas et al., “Phototherapy of Bladder Cancer: Dose/Effect Relationships,” Journal of Urology, 136:525-528 (1986).Applicant
• Henderson et al., An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy, Cancer Research 57: 4000-4007 (1997).Applicant
• Jacka et al., “A Lamp for Cancer Phototherapy”, Aust. J. Phys., 36:221-226 (1983).Applicant
• Jiang et al., “Selective Depletion of a Thymocyte Subset in Vitro with an Immunomodulatory Photosensitizer”, Clin. Immunol., 91(2):178-87 (1999).Applicant
• Jiang et al., “Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems”, J. Controlled Release, 19:41-58 (1992).Applicant
• Kashtan et al., “Photodynamic Therapy of Colorectal Cancer Using a New Light Source from In Vitro Studies to a Patient Treatment”, Dis. Colon. Rectum., 39(4):379-383 (1996).Applicant
• Kessel et al., Photosensitization with bacteriochlorins, Photochem. Photobiol. 58(2): 200-203 (1993).Applicant
• Kozyrev et al., Effect of substituents in OsO4 reactions of metallochlorins regioselective synthesis of isobacteriochlorins and bacteriochlorins, Tetrahedron Letters 37(22): 3781-3784 (1996).Applicant
• Kreimer-Birnbaum, M., “Modified Porphyrins, Chlorins, Phthalocyanines, and Purpurins: Second-Generation Photosensitizers for Photodynamic Therapy”, Seminars in Hematology 26(2):157-173 (1989).Applicant
• Latham et al., “Biophotonics Applications of High-Power Semiconductor Diode Laser technology”, pp. 1-3 (1998).Applicant
• Lin et al., “Skin Necrosis due to Photodynamic Action of Benzoporphyrin Depends on Circulating Rather than Tissue Drug Levels: Implications for Control of Photodynamic Therapy”, Photochem. Photobiol., 68(4):575-583 (1998).Applicant
• Marcus, S. L., Photodynamic therapy of human cancer, Proc. of the IEEE 80(6): 869-889 (1992).Applicant
• Marcus, S.L., “Photodynamic Therapy of Human Cancer”, Proceedings of the IEEE, 80(6):869-889 (1992).Applicant
• Margaron et al., “Photodynamic therapy inhibits cell adhesion without altering integrin expression”, Biochimica et Biophysica Acta, 1359:200-210 (1997).Applicant
• McMillan et al., “Tumor growth inhibition and regression induced by photothermal vascular targeting and angiogenesis inhibitor retinoic acid”, Cancer Lett., 137:35-44 (1999).Applicant
• Meerovich et al., “Photosensitizer for PDT based on phosphonate phthalocyanine derivative”, Proc. SPIE-INT. Scc. Opt. Engl., 2924:86-90 (1996).Applicant
• Merck Manual of Diagnosis and Therapy, 17th edition (Beers & Berkow, eds., 1999), pp. 816-817 and 1654-1657.Applicant
• Mew et al., “Ability of Specific Monoclonal Antibodies and Conventional Antisera Conjugated to Hematoporphyrin to Label and Kill Selected Cell Lines Subsequent to Light Activation”, Cancer Res., 45:4380-4386 (1985).Applicant
• Mew et al., “Photoimmunotherapy: Treatment of Animal Tumors with Tumor-Specific Monoclonal Antibody-Hematoporphyrin Conjugates”, Journal of Immunology, 130(3):1473-1477 (1983).Applicant
• Middleton et al., “Synthetic Biodegradable Polymers as Medical Devices”, Medical Plastics & Biomaterials, pp. 30-39 (1998).Applicant
• Millson et al., “Ex-Vivo Treatment of Gastric Helicobacter Infection by Photodynamic Therapy”, J. of Photochemistry and Photobiology B: Biology, 32:59-65 (1996).Applicant
• Nakatani et al., “Chemistry and biochemistry of Chinese drugs. VII. Cytostatic pheophytins from silkworm excreta, and derived photocytotoxic pheophorbides”, Chem. Pharm. Bull., 29(8):2261-2269 (1981).Applicant
• Nemoto et al., “Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice”, Brit. J. Cancer, 67(5):893-897 (1993).Applicant
• North et al., “Viral Inactivation in Blood and Red Cell Concentrates with Benzoporphyrin Derivative”, Blood Cells 18: 129-140 (1992).Applicant
• Pandey et al., “Shedding some light on tumours”, Chem. Indust., 1998:739-743 (1998).Applicant
• Pandey et al., Comparative in vivo sensitizing efficacy of porphyrin and chlorin dimers joined with ester, ether, carbon-carbon or amide bonds, J. Molecular Recognition 9: 118-122 (1996).Applicant
• Parrish, J.A., “Photobiologic Consideration in Photoradiation Therapy”, Porphyrin Photosensitization, Kessel, D. and T.M. Dougherty (Eds.) New York: Plenum Press, 1983 pp. 91-108.Applicant
• Pittau et al., “An Inexpensive Light Source for Oncologic Photodynamic Therapy”, IEEE Eng. Med. Biol., pp. 105-106 (1998).Applicant
• Renno et al., “Photodynamic Therapy Using Lu-Tex Induces Apoptosis In Vitro, and its Effect is Potentiated by Angiostatin in Retinal Capillary Endothelial Cells”, Investigative Opthalmol. & Visual Sci., 41(12):3963-3971 (2000).Applicant
• Rimington et al., Preparation and photosensitizing properties by hematoporphyrin ethers, Free Rad. Res. Comms. 7(3-6): 139-142 (1989).Applicant
• Ruebner et al., “Carrier Systems in PDT II: Accumulate Strategies of Biotin-Avidin Coupled Photosensitizers Developed On Cultured Tumor Cells”, SPIE, 2625:328-32 (1996).Applicant
• Rungta et al., Purpurinimides as photosensitizers: effect of the presence and position of the substituents in the in vivo photodynamic efficacy, Bioorg. Medicinal Chem. Letters 10: 1463-1466 (2000).Applicant
• Savellano et al., “Pegylated BPD Verteporfin C225 Anti-EGF Receptor Direct Covalent Linkage Photosensitizer Immunoconjugates”, Photochem. Photobiol., 69:38S (1999).Applicant
• Savitsky et al., “Avidin-Biotin System for Targeting Delivery of Photosensitizers and Other Cytotoxic Agents Into Malignant Tissues”, SPIE 3191:243-53 (1997).Applicant
• Schmidt et al., “Size-dependent Two-Photon Excitation pectroscopy of CdSe Nanocrystals”, Physical Review B, 53(19):12629-12632 (1996).Applicant
• Schmidt-Erfurth et al., “In Vivo Uptake of Liposomal Benzoporphyrin Derivative and Photothrombosis in Experimental Corneal Neovascularization”, Lasers in Surgery and Medicine, 17:178-188 (1995).Applicant
• Schmidt-Erfurth et al., In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization, Lasers in Surgery and Med. 17: 178-188 (1995).Applicant
• Schmidt-Erfurth et al., “Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples”, Graefe's Arch. Clin. Exp. Ophthamol., 236:365-74 (1998).Applicant
• Schmidt-Erfurth et al., “Photodynamic Therapy of Experimental Choroidal Melanoma Using Lipoprotein-delivered Benzoporphyrin”, Opthalmol., 101:89-99 (1994).Applicant
• Sharman et al., “Novel water-soluble phthalocyanines substituted with phosphonate moieties on the benzo rings”, Tetrahedron Lett., 37(33):5831-5834 (1996).Applicant
• Sigsestad et al., “Chemical Modification of Normal Tissue Damage Induced by Photodynamic Therapy”, British Journal of Cancer, 74(Suppl.37):S89-92 (1996).Applicant
• Spikes, J.D., Porphyrins and related compounds as photodynamic sensitizers, Annals of the New York Academy of Sciences 244: 496-508 (1975).Applicant
• Stedman's Medical Dictionary, 26th Edition, (Williams & Wilkens, 1995), pp. 268, 276-280, 726-727, 1165, 1182, and 1571-72.Applicant
• Sternberg et al., “Porphyrin-based Photosensitizers for Use in Photodynamic Therapy”, Tetrahedron, 54:4151-4202 (1998).Applicant
• Su, F., Photodynamic Therapy: A Maturing Medical Technology, OE-Reports, SPIE, Feb. 2000, available at http://www.spie.org/web/oer/february/feb00/phototherapy.html.Applicant
• Szeimies et al., “A New Light Source for PDT of Skin Lesions”, http://www.lumacare.com/paper3.htm, 2 pages (after 1993).Applicant
• Szeimies et al., “A Possible New Incoherent Lamp for Photodynamic Treatment of Superficial Skin Lesions”, Acta Derm Venereol, 74:117-119 (1994).Applicant
• Taber's Cyclopedic Medical Dictionary, 14th edition (C. L. Thomas, Ed.), Philadelphia: F.A. Davis Company, pp 63 (1983).Applicant
• Tomio et al., “Effect of Hematoporphyrin and Red Light on AH-130 Solid Tumors in Rats”, ACTA Radiologica Oncol., 22:49-53 (1983).Applicant
• Umemura et al., “Recent Advances in Sonodynamic Approach to Cancer Therapy,” Ultrasonics Sonochemistry, 3:S187-S191 (1996).Applicant
• Warwick, R.I., “Infinite Machines' Subsidiary Receives Positive Results in Photodynamic Therapy Tests”, BW Healthwire, http://biz.yahoo.com/bw/97/06/18/imci_y000_1.html, 2 pages (1997).Applicant
• Whitehurst et al., “Development of an Alternative Light Source to Lasers for Photodynamic Therapy: 1. Comparative In Vitro dose Response Characteristics”, Lasers in Med. Sci., 8:259-267 (1993).Applicant
• Wieman et al., “(418) Photodynamic Therapy (PDT) of Locally Recurrent Breast Cancer (LRBC) with Lutetium Texaphyrin (Lutrin)”, American Society of Clinical Oncology, 18:111A (1999).Applicant
• Wilder-Smith et al., “(G1546) Photoeradication of Helicobacter pylori in Humans: Phase 1 Study”, AGA Abstracts Gastroenterology, 116(4):A354 (1999).Applicant
• Woodburn et al., Evaluation of porphyrin characteristics required for photodynamic therapy, Photochem. Photobiol. 55(5): 697-704 (1992).Applicant
• Yamamoto, T., “Suppression of tumors by the photodynamic action of phytochlorin sodium”, Medicine and Biology, 90(4):161-164, English translation and certificate of translation included, 4 pages (Apr. 10, 1975).Applicant
• Yamamoto et al, “Photoradiation therapy, phytochlorin and visible light”, Prevention and Detection of Cancer, Part 1, Prevention. vol. 2, Etiology-Prevention Methods, Proceedings of the Third International Symposium on Detection and Prevention of Cancer held Apr. 26, 1976 in New York, N.Y., 1(2):1789-1802 (1978).Applicant
• Yamamoto et al., “Effect of phytochlorin on transplantable cancer cells”, Medicine and Biology, 89(6):433-438, English translation and certificate of translation included, 7 pages (Dec. 10, 1974).Applicant
• Yamamoto et al., “Photodynamic effects on the nucleic acids of cancer cells sensitized by sodium phytochlorin”, Medicine and Biology, 90(6):397-400, English translation and certificate of translation included, 4 pages (Jun. 10, 1975).Applicant
• Yumita et al., “The Combination Treatment of Ultrasound and Antitumor Drugs on Yoshida Sarcoma”, Japan J. Hyperthermic Oncology, 3(2):175-182 (1987).Applicant
• Yumita et al., “Sonodynamically Induced Antitumor Effect of Gallium-Porphyrin Complex by focused Ultrasound on Experimental Kidney Tumor”, Cancer Letters, 112:79-86 (1997).Applicant